Group items tagged

GSK submits sNDA for Promacta to FDA for severe aplastic anaemia treatment

Germany based drug discovery firm Evotec has entered into a research collaboration and licensing deal with Swiss biopharmaceutical firm Debiopharm Group to research and develop new cancer treatments

The US Food and Drug Administration (FDA) has now approved the use of Omalizumab, commercially known as Xolair, for the treatment of chronic hives

Germany-based pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).

GSK has received approval from FDA for its Tanzeum subcutaneous injection to improve glycemic control, along with diet and exercise, in adult patients with type 2 diabetes.

PBR Staff Writer Published 27 March 2014 The European Commission (EC) has granted marketing authorization for GlaxoSmithKline's (GSK's) once-weekly diabetes treatment, Eperzan (albiglutide). The drug is indicated for the treatment of type 2 diabetes mellitus in adults, to improve glucose control as monotherapy, when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to contraindications or intolerance.

Patients with advanced non-small cell lung cancer may have tumour biopsy replaced with a simple blood test to assess their treatment options.

Final results from the Phase III FLAURA trial investigating AstraZeneca's Tagrissofinal reinforce the therapy as the SOC for first-line treatment of patients with EGFRm advanced NSCLC.

Roche's Tecentriq: Results demonstrated that first-line treatment of patients with advanced non-small cell lung cancer and high programmed cell death ligand-1 expression who used Roche's Tecentriq monotherapy resulted in improved overall survival compared with platinum-based chemotherapies.

Kanyakumari to Trivandrum Taxi Service - Car Rental and Outstation Cab Booking Kanyakumari to Trivandrum distance: 91 km, estimated travel time: 2 hours and 50 minutes Trivandrum, officially known as Thiruvananthapuram, is Kerala's capital and largest city. The city is famous for its ancient temples, museums, institutions, seaport, art galleries, beaches, backwaters, and Ayurvedic treatments. Many patients from Kanyakumari travel to Trivandrum for Ayurvedic treatments and wellness therapies at authentic centres. Patients and elderly people need a comfortable and safe ride, so they prefer a reliable Kanyakumari to Trivandrum cab service. Sree Padmanabhaswamy Temple is a popular temple in Trivandrum. Pilgrims from Kanyakumari often visit Trivandrum to witness its architectural brilliance. Families and groups of friends visit beaches like Kovalam and Varkala to spend quality time together and make their trip memorable. Trivandrum Zoo, or Magic Planet, is perfect for a family vacation. The Kanyakumari to Trivandrum distance is just 91 km, and it takes around 3 hours by car.

Otsuka and Lundbeck has received approval from Health Canada to use its intramuscular (IM) once-monthly injectable formulation 'Abilify Maintena' for the maintenance treatment of schizophrenia in stabilized adult patients.

US-based BioMarin Pharmaceutical has selected a new drug development candidate, BMN 250, for the treatment of Sanfilippo B syndrome or Mucopolysaccharidosis type IIIB (MPS IIIB).

PBR Staff Writer Published 25 February 2014 Bristol-Myers Squibb (BMS) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV).

PBR Staff Writer Published 21 February 2014 Israel-based Pluristem Therapeutics has submitted its application to the US Food and Drug Administration seeking Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells for the treatment of severe preeclampsia.

PBR Staff Writer Published 24 February 2014 US-based biotechnology firm Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) of its Kalydeco (ivacaftor) for the treatment of people with cystic fibrosis (CF).

Scottish biotechnology firm TC BioPharm (TCB) and Japanese immuno-cell therapy company Medinet have entered into a strategic collaboration to develop a new treatment for different types of cancer.

PBR Staff Writer Published 01 May 2014 The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) Incruse Ellipta (umeclidinium) for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is a once-daily long-acting muscarinic antagonist (LAMA), a type of bronchodilator also known as an anticholinergic.